| Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia (NCT04526795) | M.D. Anderson Cancer Center | 2021-04-09 |
| Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies (NCT04681105) | City of Hope Medical Center | 2020-11-18 |
| Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer (NCT03739606) | City of Hope Medical Center | 2020-10-20 |
| Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia (NCT04188405) | M.D. Anderson Cancer Center | 2020-05-17 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (NCT03878524) | OHSU Knight Cancer Institute | 2020-04-01 |
| Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant (NCT03807063) | Fred Hutchinson Cancer Center | 2020-01-02 |
| Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy (NCT03630991) | M.D. Anderson Cancer Center | 2018-10-11 |
| Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia (NCT03576547) | M.D. Anderson Cancer Center | 2018-06-26 |
| Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation (NCT03246906) | Fred Hutchinson Cancer Center | 2017-09-11 |
| Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant (NCT02861417) | M.D. Anderson Cancer Center | 2016-08-05 |
| Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia (NCT02730195) | Emory University | 2016-05-01 |
| Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT (NCT02728700) | Stanford University | 2016-02-01 |
| Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML (NCT02311998) | M.D. Anderson Cancer Center | 2015-04-16 |
| Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD (NCT02220985) | Fred Hutchinson Cancer Center | 2015-03-23 |
| Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia (NCT02115295) | M.D. Anderson Cancer Center | 2014-05-19 |
| Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia (NCT01904136) | M.D. Anderson Cancer Center | 2014-04-22 |
| Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies (NCT01823198) | M.D. Anderson Cancer Center | 2013-06-11 |
| Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant (NCT01822509) | National Cancer Institute (NCI) | 2013-05-16 |
| Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib (NCT01746836) | M.D. Anderson Cancer Center | 2013-01-17 |
| Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies (NCT01527045) | Fred Hutchinson Cancer Center | 2012-09-25 |
| Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer (NCT00789776) | Fred Hutchinson Cancer Center | 2008-10-13 |
| Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer (NCT00105001) | Fred Hutchinson Cancer Center | 2004-11-01 |